Vireo Growth (VREOD) vs. Its Peers Critical Review

Vireo Growth (OTCMKTS:VREOD) is one of 907 public companies in the “Pharmaceuticals” industry, but how does it weigh in compared to its competitors? We will compare Vireo Growth to similar businesses based on the strength of its risk, dividends, profitability, analyst recommendations, earnings, valuation and institutional ownership.

Volatility and Risk

Vireo Growth has a beta of 1.78, meaning that its stock price is 78% more volatile than the S&P 500. Comparatively, Vireo Growth’s competitors have a beta of -3.36, meaning that their average stock price is 436% less volatile than the S&P 500.

Earnings and Valuation

This table compares Vireo Growth and its competitors top-line revenue, earnings per share and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
Vireo Growth	$268.77 million	-$68.11 million	-3.02
Vireo Growth Competitors	$3.47 billion	$3.11 billion	539.22

Vireo Growth’s competitors have higher revenue and earnings than Vireo Growth. Vireo Growth is trading at a lower price-to-earnings ratio than its competitors, indicating that it is currently more affordable than other companies in its industry.

Analyst Recommendations

This is a breakdown of current ratings and target prices for Vireo Growth and its competitors, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Vireo Growth	1	0	0	0	1.00
Vireo Growth Competitors	7614	13710	25587	996	2.42

As a group, “Pharmaceuticals” companies have a potential upside of 29.18%. Given Vireo Growth’s competitors stronger consensus rating and higher possible upside, analysts plainly believe Vireo Growth has less favorable growth aspects than its competitors.

Profitability

This table compares Vireo Growth and its competitors’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Vireo Growth	-23.37%	-19.76%	-7.15%
Vireo Growth Competitors	-2,498.12%	-250.15%	-17.02%

Institutional & Insider Ownership

32.8% of shares of all “Pharmaceuticals” companies are held by institutional investors. 3.8% of Vireo Growth shares are held by company insiders. Comparatively, 14.1% of shares of all “Pharmaceuticals” companies are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Summary

Vireo Growth competitors beat Vireo Growth on 9 of the 13 factors compared.

About Vireo Growth

Goodness Growth Holdings, Inc. operates as a cannabis company in the United States. The company cultivates, processes, and distributes medical and adult-use cannabis products. It sells cannabis products through its network of Green Goods and other Goodness Growth branded retail dispensaries and third-party dispensaries in Maryland, Minnesota, and New York. The company was formerly known as Vireo Health International Inc. and changed its name to Goodness Growth Holdings, Inc. in June 2021. Goodness Growth Holdings, Inc. is headquartered in Minneapolis, Minnesota.